UK-based drug companies AstraZeneca and GSK could be affected by Trump’s next decision, as Karl Matchett reports ...

If the tariff-loving Trump goes ahead with his plans, it will hit AstraZeneca - the most valuable company on the UK stock ...

Johnson & Johnson’s Joaquin Duato is no longer the highest paid CEO in pharma. Meanwhile, just two women make the top 10.

InterGrain is progressing two major capital works projects, aimed at boosting capacity and expanding the range of crops in ...

Many drugs use active ingredients that are manufactured outside the U.S., among them the anticoagulant heparin, which 12 million patients use each year. Meanwhile, AstraZeneca's Chairman Michel Demaré ...

The Oscars of accounting will emanate again from the Roundhouse in London on 30 September, but before the accounting glitterati walk the red carpet or ...

CEO Emma Walmsley said the company has been anticipating tariffs on the industry and is “confident” the company can navigate through it, Ashleigh Furlong and Ruth David of Bloomberg reports. The U.S.

Ohio Attorney General Dave Yost is pushing to take a leading role in a federal securities lawsuit that accuses pharmaceutical ...

The UK Government has announced a £600m ($764m) funding pot to create a new Health Data Research Service, reducing red tape ...

The research service, set to begin from the end of 2026, will provide one secure and easy-to-use data location, allowing ...